Second Sight Medical Products Inc. (EYES) Stock Price Up 5.1%
Second Sight Medical Products Inc. (NASDAQ:EYES)’s share price rose 5.1% during mid-day trading on Monday . The company traded as high as $4.17 and last traded at $4.14, with a volume of 175,326 shares traded. The stock had previously closed at $3.94.
Several analysts have recently commented on the company. Rodman & Renshaw reaffirmed a “buy” rating and issued a $16.00 target price on shares of Second Sight Medical Products in a research report on Tuesday, July 26th. Zacks Investment Research raised Second Sight Medical Products from a “sell” rating to a “hold” rating in a research report on Tuesday, April 12th.
The firm’s market capitalization is $155.79 million. The company has a 50 day moving average of $3.88 and a 200 day moving average of $4.45.
Second Sight Medical Products (NASDAQ:EYES) last announced its earnings results on Thursday, July 28th. The medical device company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.15) by $0.02. During the same quarter in the prior year, the firm earned ($0.12) earnings per share. The firm earned $1.04 million during the quarter, compared to analyst estimates of $2.66 million. Second Sight Medical Products’s quarterly revenue was down 63.0% compared to the same quarter last year. Equities analysts expect that Second Sight Medical Products Inc. will post ($0.65) EPS for the current year.
In other Second Sight Medical Products news, Chairman Robert J. Greenberg sold 8,571 shares of the company’s stock in a transaction on Thursday, June 2nd. The stock was sold at an average price of $4.10, for a total transaction of $35,141.10. Following the transaction, the chairman now owns 172,911 shares of the company’s stock, valued at approximately $708,935.10. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Second Sight Medical Products, Inc is a medical device company that develops, manufactures and markets implantable visual prosthetics to restore some functional vision to blind patients. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.